Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have bile duct cancer or gallbladder cancer that has spread to the lining of your belly (called the peritoneum).
- You must not have had chemotherapy, radiation, or immunotherapy for advanced cancer before. (If you finished adjuvant therapy more than 6 months ago, you may still be eligible.)
- You must be in reasonably good health (able to do light activities).
- Your liver and kidney function must be within acceptable limits, and you must not have brain metastases.
- You must use effective birth control during the study and for at least 14 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This trial tests a combination of low-dose chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (PD-1/PD-L1 antibody) for people with intrahepatic cholangiocarcinoma, a type of bile duct cancer inside the liver. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests a combination of a special form of chemotherapy (paclitaxel micelle) and an immunotherapy for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that has not responded to or stopped working after first treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Hear when a new Gallbladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.